Evidence map›Paper›PMID 42157944›Full record

ArticleInternational journal of biological sciences2026

Surfactant Protein B Precursor Inhibit the Progression of Resectable Non-small Cell Lung Cancer by Suppressing eIF4F-mediated Immune Evasion and Cancer Stemness.

Yongheng Wen, Hao Luo, Xintong Ji, Yushu Zheng, Liang Zhang, Dan Jian, Jing Chen, Hong Zhang, Nan-Nan Zhao, Hua Jin and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yongheng WenSchool of Medicine, Chongqing University, Chongqing, 400030, China.
Hao LuoCancer Center, Daping Hospital, Army Medical University, Chongqing, 400042, China.
Xintong JiSchool of Medicine, Chongqing University, Chongqing, 400030, China.
Yushu ZhengXinkang Hospital, Taian, 271000, China.
Liang ZhangDepartment of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China.
Dan JianCancer Center, Daping Hospital, Army Medical University, Chongqing, 400042, China.
Jing ChenSchool of Medicine, Chongqing University, Chongqing, 400030, China.
Hong ZhangDepartment of Thoracic Surgery, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.
Nan-Nan ZhaoCollege of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing,100091, China.
Hua JinDepartment of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China.
Cheng-Xiong XuSchool of Medicine, Chongqing University, Chongqing, 400030, China.
Ren-Tao WangCollege of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital, Beijing,100091, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Postoperative progression remains a major challenge in resectable non-small cell lung cancer (rNSCLC), but its factors and mechanisms are not fully understood. Here, we found that 34%-43% of rNSCLC patients have lower surfactant protein B precursor (pro-SFTPB) expression in tumor compared to adjacent tissues, and this low expression of pro-SFTPB is associated with low major pathological response to neoadjuvant chemoimmunotherapy and recurrence in rNSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungEukaryotic Initiation Factor-4FLung NeoplasmsNeoplastic Stem CellsAnimalsCell Line, TumorHumansImmune EvasionMiceEukaryotic Initiation Factor-4Fcancer stemnesseIF4Fimmune evasionpro-SFTPBresectable NSCLC

Identifiers

PMID42157944
PMCPMC13182239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.